Chimerix (NASDAQ:CMRX) Shares Pass Below 200-Day Moving Average of $1.00

Shares of Chimerix, Inc. (NASDAQ:CMRX) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.00 and traded as low as $0.90. Chimerix shares last traded at $0.93, with a volume of 182,039 shares changing hands.

Analyst Ratings Changes

CMRX has been the subject of several analyst reports. Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Monday, February 12th. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Monday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Chimerix in a research note on Friday, March 1st.

Chimerix Price Performance

The company has a market capitalization of $82.55 million, a PE ratio of -1.01 and a beta of 1.15. The firm’s 50 day moving average is $1.08 and its 200 day moving average is $1.00.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. Chimerix had a negative return on equity of 37.93% and a negative net margin of 25,337.96%. As a group, analysts predict that Chimerix, Inc. will post -0.77 EPS for the current fiscal year.

Institutional Trading of Chimerix

A number of hedge funds and other institutional investors have recently modified their holdings of CMRX. Vontobel Holding Ltd. lifted its stake in shares of Chimerix by 40.0% in the third quarter. Vontobel Holding Ltd. now owns 70,000 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 20,000 shares in the last quarter. Vance Wealth Inc. bought a new position in shares of Chimerix during the 4th quarter valued at $46,000. Assenagon Asset Management S.A. grew its holdings in shares of Chimerix by 17.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 72,719 shares during the period. Pale Fire Capital SE purchased a new stake in Chimerix during the third quarter valued at $95,000. Finally, Bank of New York Mellon Corp lifted its holdings in Chimerix by 190.0% in the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 387,638 shares during the period. 45.42% of the stock is owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.